News – Page 1153 – Endpoints News

Gladstone spinout Tenaya tackles new cures for heart failure with $50M A round

9 years ago

Is the US biopharma industry headed for a turning point in 2017?

9 years ago

GSK vet Deborah Waterhouse takes CEO spot at Viiv; Is Sanofi pondering an Actelion bid?

9 years ago

The FDA just signed off on a Formula 1 pivotal track for Sage's postpartum depression drug

9 years ago

In a rare blockbuster performance for AstraZeneca, Tagrisso comes through on lung cancer PhIII

9 years ago

Juno gets some badly needed relief after a glimpse of upbeat early data on JCAR017

9 years ago

Section 32: Ex-Google venture chief Maris pursues indie role with $230M biotech fund

9 years ago

Sarepta critic Jenkins is exiting the FDA, and Woodcock takes direct charge of the OND after a painful rupture

9 years ago

Merck is hiring as it shows off new Bay Area campus plans; Lilly, though, is reportedly laying off sales staff

9 years ago

Cerecor blasted as its second clinical roll of the dice in days comes up snake eyes

9 years ago

Rattled by immune responses, Spark will pay $30M-plus to get Selecta’s help in ending threat

9 years ago

ReNeuron’s stem cell treatment fails a small stroke study, but the biotech says it’s ready for pivotal

9 years ago

Kite adds promising leukemia responses in small CAR-T studies, then fires the starting gun on its rolling submission

9 years ago

What makes a PhII drug worth up to $665M? Researchers spell it out for Novartis

9 years ago

#ASH16: Pfizer offers a thumbs-up on OS data from PhII blood cancer study of glasdegib

9 years ago

In wake of a CAR-T restructuring, Novartis says it’s ready to hunt a pioneering OK for lead program

9 years ago

Spark’s delivery vector triggers another troubling immune reaction, but R&D team maintains hemophilia B efficacy

9 years ago

Lethally severe neurotoxicity continues to haunt Juno’s CAR-T pipeline

9 years ago

Celgene buys Acetylon, keeps what it wants and spins the rest back out as Regenacy

9 years ago

Yes, Martin Shkreli can drop his bad boy persona, at least for one moment

9 years ago

Retreating Arrowhead axes CSO in RNAi rout; Impel raises $36M for platform tech

9 years ago

21st Century Cures Act could use a second look; It's time for the FDA to open up

9 years ago

Booming CRISPR pioneer Intellia looks to double staff with new digs

9 years ago

Cutting back in the UK, Takeda spins out its top neuroscience team into a transatlantic biotech

9 years ago

First page Previous page 1150 1151 115211531154 1155 1156 Next page Last page